{"title":"Statins Do Not Impair Whole-body Fat Oxidation During Moderate-intensity Exercise in Dyslipidemic Adults","authors":"M. A. Matuszek, R. Grant","doi":"10.26644/EM.2018.012","DOIUrl":null,"url":null,"abstract":"Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for atorvastatin and 34 for rosuvastatin [2]. Physiologically, these drugs inhibit liver enzyme HMGCoA reductase, blocking cholesterol synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical activity are valuable contributors to maintaining healthy blood lipids, with exercise improving cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular disease, stroke, type 2 diabetes mellitus Research Article Exercise Medicine Open Access eISSN: 2508-9056","PeriodicalId":36798,"journal":{"name":"Swiss Sports and Exercise Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss Sports and Exercise Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26644/EM.2018.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 1
Abstract
Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in positions 1 and 7 in the USA [1]. In the same year, in Australia, atorvastatin and rosuvastatin were in positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for atorvastatin and 34 for rosuvastatin [2]. Physiologically, these drugs inhibit liver enzyme HMGCoA reductase, blocking cholesterol synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and all-cause mortality [3]. However, it is now well established that a healthy diet and regular physical activity are valuable contributors to maintaining healthy blood lipids, with exercise improving cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular disease, stroke, type 2 diabetes mellitus Research Article Exercise Medicine Open Access eISSN: 2508-9056